J Thromb Haemost:COVID-19患者血小板减少症与死亡率的关系

2020-04-18 MedSci原创 MedSci原创

血小板减少症在COVID-19患者中很常见,并且与院内死亡风险增加相关。COVID-19患者血小板数越少,死亡率越高。

严重急性呼吸综合症冠状病毒2(SARS-CoV-2)引起的急性冠状病毒病2019(COVID-19)在世界范围内迅速传播。COVID-19患者血小板减少症尚未得到充分分析。近日,血栓和凝血疾病权威杂志Journal of Thrombosis and Haemostasis上发表了一篇研究文章,该研究旨在描述COVID-19患者血小板减少症情况。

研究人员回顾性地收集了武汉市金银潭医院1476例连续就诊的COVID‐19患者住院期间的最低血小板计数,并将其分为(0-50]、(50-100]、(100‐150]或(150‐)×109/L)组,研究人员分析了最低点血小板计数和院内死亡率。

在所有患者中,238名(16.1%)患者血小板数量减少,306名(20.7%)患有血小板减少症。与幸存者相比,非幸存者年龄更大,血小板减少症的发生率更低,最低血小板计数也更低。(0-50]、(50-100]、(100-150]和(150-)组患者的院内死亡率分别为92.1%、61.2%、17.5%和4.7%。以(150-)组为对照,最低血小板计数为(100-150]、(50-100]和(0-50]的患者相对风险分别为3.42(95%CI为2.36-4.96)、9.99(95%CI为7.16-13.94)和13.68(95%CI为9.89-18.92)。

由此可见,血小板减少症在COVID-19患者中很常见,并且与院内死亡风险增加相关。COVID-19患者血小板数越少,死亡率越高。

原始出处:

Xiaobo Yang.et al.Thrombocytopenia and Its Association with Mortality in Patients with COVID‐19.Journal of Thrombosis and Haemostasis.2020.https://onlinelibrary.wiley.com/doi/10.1111/jth.14848

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2008466, encodeId=c531200846655, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Fri Mar 05 04:27:51 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297431, encodeId=fbd4129e43126, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Apr 20 12:27:51 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302843, encodeId=12da1302843ad, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Apr 20 12:27:51 CST 2020, time=2020-04-20, status=1, ipAttribution=)]
    2021-03-05 changfy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2008466, encodeId=c531200846655, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Fri Mar 05 04:27:51 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297431, encodeId=fbd4129e43126, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Apr 20 12:27:51 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302843, encodeId=12da1302843ad, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Apr 20 12:27:51 CST 2020, time=2020-04-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2008466, encodeId=c531200846655, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Fri Mar 05 04:27:51 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297431, encodeId=fbd4129e43126, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Apr 20 12:27:51 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302843, encodeId=12da1302843ad, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Apr 20 12:27:51 CST 2020, time=2020-04-20, status=1, ipAttribution=)]

相关资讯

J Thromb Haemost:严重COVID‐19患者抗凝治疗与死亡率降低有关

符合SIC标准或D-二聚体明显升高的严重COVID‐19患者给予低分子肝素为主的抗凝治疗可获得较好预后。

Ann Rheum Dis:经常使用葡糖胺与死亡率的关联

经常补充葡糖胺可降低各种原因、癌症、CVD、呼吸道和消化系统疾病导致的死亡率。

Diabetes Obes Metab:2型糖尿病患者糖化血红蛋白变异性与心血管疾病和死亡率之间的年龄特异性关系

糖化血红蛋白变异性与所有年龄段糖尿病患者的心血管疾病和死亡率密切相关。在追求最佳糖化血红蛋白目标值的同时,应关注糖化血红蛋白变异性高的患者,特别是那些糖化血红蛋白控制良好的年轻患者。

Gut:经活检证实的酒精相关肝病患者死亡率

经活检证实的ALD患者死亡风险是普通人群的5倍。没有肝硬化的ALD患者也有较高的死亡风险,因此,有必要重申在治疗这些患者时,需要提高警惕。

Heart:年龄、时期和队列效应对心脑血管疾病死亡率的影响

本研究目的旨在探讨年龄、时期或队列效应是否能解释苏格兰缺血性心脏病(IHD)和脑血管病(CeVD)死亡率的趋势和不平等。

JAHA:植入式心律转复除颤器在心衰药物试验中的应用

ICD的使用率较低,并且ICD与全因死亡率和心源性猝死的风险降低相关。